Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by clubhouse19on Feb 24, 2021 4:17pm

191 Views

Post# 32650178

Shorting stats

The last 2 weeks of reporting

Short positon douibled from 56k to 109 k

425 k shares were shorted during the same period

Day traders are plating both sides both long and short..

Short side is becoming much more prevalent and mostly done by the houses since they have no restrictions and can also naked short which is a no no for the retail player and they pay a fixed price per month on trades no limit !

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario